Oveporexton (TAK-861): A First-in-Class Orexin Agonist for Narcolepsy Type 1
On August 5, 2026, the U.S. Food and Drug Administration approved oveporexton (TAK-861), making it the first orexin receptor agonist approved for narcolepsy type 1 (NT1) and adults.¹ It’s also the first therapy to treat the disorder by restoring the neurochemical signal it destroys rather than blunting the symptoms downstream.
Narcolepsy Type 1 and Orexin Deficiency: Rationale for Orexin Agonist Therapy
An orally active, selective OX2R agonist has long been pursued as a therapeutic objective in narcolepsy drug discovery. Oveporexton represents a refined successor to the compound that first demonstrated the feasibility of this approach (Figure 1). Firazorexton (TAK-994), the first oral OX2R agonist, nearly abolished cataplexy and restored wakefulness in Phase 2 trials; however, its development was discontinued in October 2021 following dose-dependent hepatotoxicity.²⁻³
Figure 1 Chemical structure of oveporexton (TAK-861) and its related predecessor, firazorexton (TAK-994)
Oveporexton retains the [3-(3,5-difluorophenyl)-2-fluorophenyl]methyl group and 2-hydroxy-2-methylpropanoyl cap of firazorexton, adding a 4,4-difluoro substitution on the pyrrolidine ring and replacing the methanesulfonamide with an ethanesulfonamide.²⁻⁴ This redesign affords a highly selective OX2R agonist (EC₅₀ ≈ 2.5 nM; ~3000-fold over OX1), dosed at 1–2 mg twice daily versus 30–60 mg for firazorexton, and it advanced through Phase 3 without the hepatic signal associated with its predecessor.³⁻⁷
That compact, fluorine-rich pyrrolidine sulfonamide, with two contiguous stereocenters, a gem-difluoro center, and a 2-fluorinated biaryl, is the target the of following ChemAIRS® retrosynthesis.
Oveporexton Synthesis: Key Challenges and Two ChemAIRS® Routes Compared
The molecule packs a 4,4-difluoropyrrolidine core, two contiguous stereocenters (2S,3R), and a 2-fluorinated biaryl into a compact scaffold. A route has to install the gem-difluoro group, control both stereocenters, and form the biaryl bond efficiently. ChemAIRS® returned several viable routes to meet these challenges. Two are compared here: a fully precedented linear sequence from Takeda and a more convergent alternative.
Route 1: Takeda’s 14-Step Patent Synthesis of Oveporexton
Route 1 closely follows the chemistry in Takeda's patent.⁸ It starts from commercially available phenylalanine derivative 1b, which corresponds to the product of step 3 in the reported route (Scheme 1). The sequence is well precedented but long, with many bond-forming reactions, protecting-group manipulations, and functional-group interconversions. A Reformatsky reaction converts 4b to 5a and installs the gem-difluoride in the pyrrolidine core. A late-stage Suzuki cross-coupling then delivers 13a.
Scheme 1 ChemAIRS®-predicted 14-step route to oveporexton (TAK-861)
Route 2: Convergent 8-Step Oveporexton Synthesis (Longest linear sequence of 5)
Route 2 prepares two fragments separately and joins them late (Scheme 2).
Biaryl fragment. Suzuki cross-coupling of boronic acid 1a with aryl bromide 1b sets the biaryl bond. The resulting benzylic alcohol 2a is converted to benzylic bromide 6b.
Pyrrolidine fragment. Acidic removal of the Boc group from commercially available pyrrolidinone 3a gives 5b. Amide coupling of 5b with TBS-protected acid 5a installs the 2-hydroxy-2-methylpropanoyl cap and gives 6a.
Fragment union. ChemAIRS® proposed a less conventional disconnection. Deprotonative zincation of 6a⁹, then trapping with benzylic bromide 6b, forms 7b, which carries most of the oveporexton scaffold. Titanium-mediated reductive amination of the pyrrolidinone with ethanesulfonamide 7a installs the C3 sulfonamide. As in the reported synthesis, chiral resolution can be investigated to obtain the (2S,3R) enantiomer of 8a, and removal of the TBS group gives oveporexton.
Scheme 2 A convergent ChemAIRS®-inspired route to oveporexton (TAK-861)
Replacing BOP in the amide coupling with ChemAIRS® Condition Search
The amide coupling that forms 6a is the first step where a supporting module changes the proposed conditions. ChemAIRS® initially suggested BOP, which releases stoichiometric hexamethylphosphoramide (HMPA), a suspected carcinogen. Condition Search identified alternatives that do not release HMPA, including HATU, TBTU, and T3P, which can be evaluated as replacements. Considering them at the route-planning stage keeps this scale-up concern from carrying into later process development.
Figure 2 ChemAIRS® Condition Search for amide coupling of 5a and 5b: predicted conditions and alternatives
ChemAIRS®-Enabled Retrosynthetic Route Design for Oveporexton (TAK-861)
The convergent route reduces the synthesis of oveporexton from 14 linear steps to eight steps, with a longest linear sequence (LLS) of five, by assembling two fragments at a late stage. Combined with Condition Search to evaluate alternatives to potentially hazardous reagents, ChemAIRS® supports the assessment of retrosynthetic strategies and reaction conditions during route planning.
What Is ChemAIRS®?
ChemAIRS® is a computer-aided synthesis planning (CASP) platform that proposes retrosynthetic routes to existing and novel molecules, ranking them by feasibility and by access to readily available building blocks. Its Retrosynthesis module combines machine learning with encoded chemical logic, and every step remains open to interrogation, so chemists can troubleshoot a disconnection or explore alternative methodology rather than accept a route as given. The platform is built to extend a chemist's strategic reach, not to substitute for it.
References
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms. U.S. Food and Drug Administration. August 5, 2026. Accessed August 7, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
Kukkonen JP, Jacobson LH, Hoyer D, Rinne MK, Borgland SL. International Union of Basic and Clinical Pharmacology CXIV: orexin receptor function, nomenclature and pharmacology. Pharmacol Rev. 2024;76(5):625–688. https://doi.org/10.1124/pharmrev.123.000953
Arif Z, Siddiqui E, Hujjat SFZ, Khan MS, Mauhmoud A. Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1. Ann Med Surg. 2026;88:42–44. https://doi.org/10.1097/MS9.0000000000004476
Mitsukawa K, Terada M, Yamada R, et al. TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Sci Rep. 2024;14(1):20838. https://doi.org/10.1038/s41598-024-70594-1
Takeda Pharmaceutical Company Limited. Takeda announces positive results from two pivotal Phase 3 studies of oveporexton (TAK-861) in narcolepsy type 1. July 14, 2025. Accessed August 4, 2026. https://www.takeda.com/newsroom/newsreleases/2025/positive-results-phase-3-oveporexton-narcolepsy-type-1/
A study of TAK-861 for the treatment of narcolepsy type 1. ClinicalTrials.gov identifier: NCT06470828. Accessed August 4, 2026. https://clinicaltrials.gov/study/NCT06470828
A study of TAK-861 in people with narcolepsy type 1. ClinicalTrials.gov identifier: NCT06505031. Accessed August 4, 2026. https://clinicaltrials.gov/study/NCT06505031
Hattori Y, Miyanohana Y, Kajita Y, et al., inventors; Takeda Pharmaceutical Company Limited, assignee. Heterocyclic Compound and Use Thereof. US patent 2020/0247747 A1. August 6, 2020.
Lefker B, Gibson K, Spendiff M, et al., inventors; Orexia Therapeutics Limited, applicant. Bicyclic-Heterocycle Derivatives and Their Uses as Orexin-2 Receptor Agonists. WIPO Patent WO2022/051596 A1. March 10, 2022.